Legal & General Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Legal & General Group’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14,060	Closed	-$253K	–	3612
2021 Q3	$253K	Buy	14,060 +144	+1%	+$1.68K	﹤0.01%	2612
2021 Q2	$138K	Buy	13,916 +9,415	+209%	+$88.6K	﹤0.01%	2636
2021 Q1	$48K	Buy	4,501 +1,890	+72%	+$23.4K	﹤0.01%	2827
2020 Q4	$38K	Buy	+2,611	New	+$37.7K	﹤0.01%	2885

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Legal & General Group's TRIL Position: Q4 2021 in Review

Legal & General Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 14,060 shares — an estimated $253K sold.

Legal & General Group first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $253K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Legal & General Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Legal & General Group sold 14,060 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $253K.
Legal & General Group first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
Legal & General Group's Trillium Therapeutics Inc. position peaked at $253K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Legal & General Group's 13F filing for Q4 2021, filed 14 Feb 2022.